Recombinant GM-CSF is used in clinical practice for the treatment of a wide range of hematopoietic diseases, including chemotherapy-induced neutropenia, and it is also being investigated for the treatment of several other diseases (neurodegenerative, autoimmune, cancer, wound healing, etc.). This evidence concerns the gene CSF2 and Decreased total neutrophil count.